Trial Profile
Phase 1, Randomized Open Label, Multiple Dose, Parallel Study To Assess The Immunogenicity Of Multiple Subcutaneous (SC) Doses Of The Proposed Pegfilgrastim Biosimilar (PF-06881894) And Us-approved Neulasta (Registered) In Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Jun 2020
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Febrile neutropenia; Neutropenia
- Focus Therapeutic Use
- Sponsors Pfizer
- 10 Jun 2020 Results evaluating the pharmacodynamic/pharmacokinetic (PD/PK) equivalence, immunogenicity, and safety of PF-06881894 vs pegfilgrastim reference products (US- and EU-Neulasta) in healthy volunteers published in the Advances in Therapy
- 15 Aug 2018 Status changed from recruiting to completed.
- 03 Jul 2018 Planned End Date changed from 29 Jul 2018 to 25 Jul 2018.